Thus, recent findings demonstrated that angiotensin-converting enzyme (ACE) and AT1R, which are the better known components and drug-targets of RAS, significantly altered their expression and activity in CRC tissues when compared to the uninvolved colorectal mucosa, and these changes were associated with CRC progression [48,49]. This evidence concerns the gene AGTR1 and colorectal carcinoma.